MULTIPLE MYELOMA REFRACTORY
Clinical trials for MULTIPLE MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody combo offers hope for hard-to-treat multiple myeloma
Disease control ENROLLING_BY_INVITATIONThis study tests whether a new antibody drug called HuL001, combined with two standard drugs (lenalidomide and dexamethasone), is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatments. About 21 adults will receive HuL001 inje…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: HuniLife Biotechnology, Inc. • Aim: Disease control
Last updated May 26, 2026 04:46 UTC
-
Speedy CAR-T cells take on Hard-to-Treat myeloma in first human safety trial
Disease control TerminatedThis early-stage study tests a new type of CAR-T cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy, UF-KURE-BCMA, is made from a simple blood draw and has a shorter manufacturing time than standard CA…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Website aims to empower myeloma patients in their own treatment
Knowledge-focused OngoingThis study looks at whether a health technology program called All4Cure helps people with multiple myeloma become more active in managing their health. About 200 participants will fill out surveys online to measure their confidence and ability to handle their care. The goal is to…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated May 26, 2026 04:50 UTC